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ABSTRACT Anti-neutrophil cytoplasmic autoantibodies
(ANCA) are in the circulation of most patients with pauci-
immune necrotizing vasculitis and pauci-immune crescentic
glomerulonephritis. The current study demonstrates an effect
of these autoantibodies on neutrophil function in vitro. ANCA
cause normal human neutrophils to undergo an oxidative burst
and degranulate. Both ANCA phenotypes (i.e., cytoplasmic-
pattern ANCA and myeloperoxidase-specific ANCA) induce
neutrophil activation. ANCA sera and purified immunoglob-
ulins significantly increase the release ofreactive oxygen species
when compared with controls. ANCA, in a dose-dependent
manner, induce the release of primary granule contents. These
effects are markedly enhanced by priming neutrophils with
tumor necrosis factor. Flow cytometry studies demonstrate the
presence of myeloperoxidase on the surface of neutrophils after
cytokine priming, indicating that primed neutrophils have
ANCA antigens at their surfaces to interact with ANCA. These
observations suggest an in vivo pathogenetic role for ANCA.
We propose that, in patients with necrotizing vasculitis,
ANCA-induced release of toxic oxygen radicals and noxious
granule enzymes from cytokine-primed neutrophils could be
mediating vascular inflammation.
Systemic necrotizing vasculitis and crescentic glomerulone-
phritis can be categorized on the basis of three immunohis-
tologic patterns of vascular immunoglobulin deposition: (i)
granular deposition indicative of immune complex-mediated
disease, (ii) linear deposition indicative of anti-basement
membrane antibody-mediated disease, and (iii) no or scanty
deposition, also referred to as pauci-immune disease (1). This
third category is the most common (1-4) and includes We-
gener granulomatosis and most polyarteritis nodosa. There-
fore, one of the most perplexing issues with respect to
systemic necrotizing vasculitis and crescentic glomerulone-
phritis is the pathogenesis of vascular inflammation in the
absence of immunoglobulin deposition in vessel walls.
Anti-neutrophil cytoplasmic autoantibodies (ANCA) are in
the serum of -80% of patients with pauci-immune necrotiz-
ing vasculitis (1). The vascular lesions form a continuum from
renal-limited necrotizing and crescentic glomerulonephritis
to systemic vasculitis (1, 5-15). ANCA react with constitu-
ents of neutrophil primary granules and monocyte lysosomes
(1, 6, 16-18). Two different ANCA types have been recog-
nized by indirect immunohistology. Within each category
there are multiple specificities. One ANCA type, C-ANCA,
produces cytoplasmic staining and is usually specific for the
serine proteinase, proteinase 3 (19, 20). The second ANCA
type (perinuclear-pattern ANCA), which usually has speci-
ficity for myeloperoxidase (MPO-ANCA), produces artifac-
tual perinuclear staining on alcohol-fixed neutrophils but
produces cytoplasmic staining on formalin-fixed cells (1, 6,
18).
We postulated that these autoantibodies are capable of
activating neutrophils and may be pathogenic; this idea was
tested by measuring in vitro the release of reactive oxygen
species (ROS) and primary granule contents from ANCA-
stimulated human neutrophils. The data support the hypoth-
esis that ANCA may be involved in the pathogenesis of
necrotizing vasculitis and glomerulonephritis.
MATERIALS AND METHODS
Serum and Immunoglobulin Samples. ANCA sera were
obtained from patients with pauci-immune necrotizing and
crescentic glomerulonephritis, 75% of whom had extrarenal
vasculitis. A positive ANCA serology was determined by
using a standard indirect immunofluorescence microscopy
assay and by ELISA (6, 21). Ofthe 13 ANCA sera used in this
study, 7 were C-ANCA and 6 were MPO-ANCA. All of the
perinuclear-pattern ANCA were found to have specificity for
MPO with an MPO-specific ELISA (6). None ofthe C-ANCA
sera reacted with MPO, but 4 of these sera reacted by ELISA
with proteinase 3 (20).
Purified immunoglobulins were prepared by sequential
ammonium sulfate precipitation and DEAE-Sephacel chro-
matography (Pharmacia LKB) from five C-ANCA, six MPO-
ANCA, and two normal human sera as well as from serum
from patients with active lupus nephritis (n = 4), anti-
glomerular basement membrane antibody-induced glomeru-
lonephritis (n = 1), ANCA-negative pauci-immune necrotiz-
ing glomerulonephritis (n = 1), and other glomerular lesions
(n = 3). The IgGs were negative for endotoxin by a Limulus
amoebocyte lysate assay (sensitivity, 0.1 ng/ml). Prior to
use, the IgGs were centrifuged to remove aggregates. For
comparative purposes, a polyclonal anti-human MPO anti-
body (Dako, Carpinteria, CA), a monoclonal anti-human
MPO antibody (Dako), and a monoclonal anti-human DNA
antibody (Chemicon) were used.
F(ab')2 from an MPO-ANCA IgG were prepared by using
pepsin cleavage followed by a protein A separation column
(ImmunoPure Fab preparation kit; Pierce).
Chemiluminescence Studies. Chemiluminescence studies
(22, 23) were performed with normal human neutrophils (6).
Assays were performed with 5 x 106 cells per ml pretreated
with cytochalasin B (5 ,g/ml) (24) and then placed in cold
luminol (4°C). Chemiluminescence measurements were per-
formed by an integrating photometer (model 3000; SAI Tech-
nology, San Diego). A 1:20 dilution of serum or IgG (50
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ILg/ml) was used for each time point, and each condition was
assayed in quadruplicate (measurements differed by <10%).
Analysis of unstimulated cells provided a baseline, whereas
phorbol 12-myristate 13-acetate (1 ,ug/ml)-treated neutro-
phils were used as positive controls. Duplicate or triplicate
experiments (which differed by <20%) were compared, and
the mean cpm were calculated for each sample at 30 min.
To assess the specificity of these chemiluminescence as-
says for the products of a respiratory burst, the inhibitory
effects of catalase (final concentration of 15 units/ml; no.
C-100, Sigma) were analyzed. Since chemiluminescence may
also measure the activation of several mixed-function oxi-
dases, ANCA-induced ROS production was measured from
the neutrophils of a patient with chronic granulomatous
disease (25).
Superoxide Generation Assay. Superoxide was measured
by the superoxide dismutase-inhibitable reduction of ferri-
cytochrome c as determined by scanning between 540 and
560 nm with a double-beam spectrophotometer (model 118C;
Cary, Palo Alto, CA) (26, 27). In these experiments cyto-
chalasin B was not used. For each experiment, 1 x 106 cells
were incubated with IgG at 100 j&g/ml. The effects of
MPO-ANCA, C-ANCA, and control IgG in four replicate
experiments were compared with the effect of phorbol 12-
myristate 13-acetate (1 jig/ml). The selection of these par-
ticular IgGs was made on the basis of availability, similarity
of the clinical course of the patients, and a comparable degree
of activation in the chemiluminescence studies. In these
studies we explored the effects of priming neutrophils for 15
min at 370C with tumor necrosis factor a (TNF-a; Genzyme)
at 2 ng/ml (28-31).
Degranulation Assays. (-glucuronidase activity was as-
sessed by the cleavage of phenolphthalein from phenolphtha-
lein glucuronic acid and compared with a standard curve (32).
Results are expressed as the amount of phenolphthalein
released per 3.6 x 106 cells per ml. Lactate dehydrogenase
assays assessed cell viability by monitoring the decrease in
absorbance at 340 nm obtained by the conversion of pyruvate
to lactate and concomitant conversion of NADH to NAD+
(33). Lactate dehydrogenase values are reported in units/
liter; the values of assay supernatants were compared to a
Triton X-100 cell lysate. N-Acetylglucosaminidase (NAG)
(another marker of primary granule degranulation) was as-
sessed by using a modified fluorometric assay (34).
For each assay, 3.6 x 106 purified neutrophils were pre-
incubated for 5 min with cytochalasin B (final concentration
of 5 ,ug/ml). The cells were primed with TNF (2 ng/ml)
(27-30) or, for comparative purposes, Hanks' balanced salt
solution with calcium (13 mM) and magnesium (4 mM)
without TNF and incubated at 37°C for 15 min. Analysis of
unstimulated cells provided a baseline, whereas fMet-
Leu-Phe (0.1 ,uM)- or Triton X-100 (0.5%)-stimulated cells
served as positive controls. To demonstrate a dose-
dependent relationship, ANCA IgG (500-50 ,g/ml), mouse
anti-human MPO (15.2-0.475 ,g/ml), polyclonal rabbit anit-
human MPO (750-0.95 ,ug/ml), and mouse anti-human DNA
(15.2-0.475 jig/ml) were used to stimulate polymorphonu-
clear leukocyte degranulation during a 1-hr incubation.
Flow Cytometry Studies. Flow cytometry was used to
demonstrate the presence of ANCA antigen, specifically
MPO, on the surface of neutrophils. Isolated neutrophils
were suspended in 1.0% bovine serum albumin (Sigma)/
phosphate-buffered saline at 0.5 x 106 cells per ml. Cells were
preincubated with either 0.1 ,uM fMet-Leu-Phe or TNF (2
ng/ml) from 30 sec to 30 min. The reactions were terminated
with 1.0% paraformaldehyde, which immobilized proteins at
the cell surface, and centrifuged at 40C. The pellet was
resuspended and incubated for 15 min in a 1:100 dilution of
polyclonal anti-human MPO, MPO-ANCA IgG, or the
F(ab')2 MPO-ANCA preparation. The cells were washed
with 1.0% bovine serum albumin/phosphate-buffered saline
(40C) and incubated with goat F(ab')2 anti-rabbit immuno-
globulin conjugated to fluorescein isothiocyanate (Tago) or
with a goat F(ab')2 anti-human immunoglobulin conjugated to
fluorescein isothiocyanate (Tago). After another 15-min in-
cubation period at 40C, the cells were washed twice. Analysis
of surface antigen expression was performed on a EPICS
Coulter model 753 cell sorter (Coulter) at 488 nm. Control
studies were performed without a primary antibody, with
normal rabbit serum, and with purified normal and disease
control human IgGs.
Statistical Analysis. All statistical differences between
groups were determined by Student's t test. Differences
between multiple groups were found by one-way analysis of
variance. When the one-way analysis of variance showed
significant differences between groups, Fisher's least signif-
icant difference method was performed to compare individual
pairs of group means. In all cases, raw data were used for
analysis without the use of transformed data.
RESULTS
Release of ROS. The release of ROS from neutrophils was
measured by using luminol-dependent chemiluminescence
(Fig. 1). Thirteen ANCA-positive (7 C-ANCA and 6 MPO-
ANCA) sera were compared with 5 normal sera (Fig. lA).
ROS release was markedly enhanced when neutrophils were
incubated with ANCA sera (35.7 x 103 ± 28.6 cpm) as
compared with normal sera (2.2 x 103 ± 2.0 cpm; P < 0.02).
MPO-ANCA results (44.1 x 103 + 32.1 cpm) were not
statistically different from C-ANCA results (28.4 x 103 +
25.4 cpm), but both were different from the normal sera (P <
0.05).
ANCA IgGs caused increased ROS release from neutro-
phils (28.8 x 103 ± 27.2 cpm) as compared with disease
controls (4.5 x 103 ± 4.3 cpm; P < 0.02) (Fig. LA). MPO-
ANCA results (39.6 x 103 ± 31.3 cpm) were not different
from C-ANCA results (15.9 x 103 + 15.9 cpm), but both were
greater than control IgGs (P < 0.01). The time course of
activation was similar for both MPO-ANCA and C-ANCA
(Fig. 1B).
The specificity of the chemiluminescence assay for ROS
release was explored. In luminol-dependent chemilumines-
cence experiments, catalase diminished ANCA-induced ROS
release by 70%o (20 x 103 cpm without versus 4.3 x 103 cpm
with catalase at 30 min). These results are not surprising since
luminol-dependent chemiluminescence measures an MPO-
dependent pathway of oxygen metabolism (20). In another
series of experiments, the most potent MPO-ANCA IgG could
not induce ROS release from neutrophils from a patient with
chronic granulomatous disease (CGD) (Fig. 1B), whereas this
MPO-ANCA IgG was capable of degranulating CGD neutro-
phils. The results of the catalase and CGD experiments render
unlikely the possibility that the chemiluminescence experi-
ments measured nonspecific emission of light.
An F(ab')2 was prepared from an MPO-ANCA IgG. The
F(ab')2 fraction had no effect on neutrophils when used by
itself. In the presence of TNF, however, the F(ab')2 fraction
was able to release ROS with a time course similar to that of
the parent IgG (Fig. 1B). The release of ROS by TNF alone
was not different than that observed for resting cells.
When superoxide release was assessed by superoxide
dismutase-inhibitable reduction of ferricytochrome c, TNF
priming was an important facilitator of activation, as has been
observed by others (28-31). Four ANCA IgGs were com-
pared with four control IgGs. When ANCA IgGs were
incubated without TNF, no superoxide release was ob-
served. In a continuous assay, ANCA IgGs in the presence
ofTNF resulted in superoxide release, whereas a control IgG
had no effect (Fig. 2). Similar activation kinetics were ob-
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FIG. 1. ANCA-induced release ofROS measured by chemilumi-
nescence. (A) Sera or purified immunoglobulins were incubated with
neutrophils. Replicate experiments were compared, and the mean
cpm at 30 min were calculated. Thirteen ANCA sera were compared
with 5 normal sera. Eleven ANCA IgG were compared with 2 normal
IgG as well as with IgG from 9 disease control patients. A, MPO-
ANCA; A, C-ANCA; o, normal IgGs; e, normal serum samples in the
normal sera column and disease controls in the control IgG column.
The mean cpm for each ofthe four groups is indicated by a horizontal
line. (B) The time courses ofROS release from neutrophils incubated
with C-ANCA IgG (line A), MPO-ANCA IgG (line B), and Good-
pasture syndrome IgG (line D) are compared. The most potent
MPO-ANCA did not stimulate neutrophils obtained from a patient
with chronic granulomatous disease (line E). MPO-ANCA F(ab')2 in
the presence ofTNF stimulated ROS release (line C), whereas there
was no stimulation without TNF. Values for unstimulated cells were
comparable to the observations described by lines D and E. TNF was
not used in experiments A, B, D, or E.
served when an MPO-ANCA IgG-induced superoxide re-
lease was compared with ROS release by using luminol-
dependent chemiluminescence (Fig. 3).
In view of the observations that ANCA react with primary
granule constituents and that MPO-ANCA react in particular
with purified MPO (1, 6, 17, 18), we explored the effects of
a commercial polyclonal anti-human MPO antibody in sev-
eral activation assays. This anti-MPO antibody at 100 jig/ml
caused the release of ROS in the chemiluminescence assay
(44.8 x 103 + 17.0 cpm; n = 5) and the superoxide assay (7.3
nmol). Although TNF priming facilitated these effects, at the
concentration of antibody used in these experiments, TNF
was not essential for activation.
MPO-ANCA
TIME (minutes)
FIG. 2. ANCA-induced superoxide release. Superoxide was
measured in a continuous assay by the superoxide dismutase-
inhibitable reduction of ferricytochrome c. The effects of an MPO-
ANCA, C-ANCA, and control IgG in four replicate experiments are
shown in comparison with the effects of phorbol 12-myristate 13-
acetate (PMA) at 1 ,.g/ml.
Degranulation of Primary Granules. In addition to ANCA-
induced oxygen metabolism, we wondered whether release
of noxious enzymes from primary granules could also be
triggered by ANCA. Primary granule degranulation was
assessed by j-glucuronidase (Fig. 4) and NAG release. The
effects of 10 ANCA IgGs (500 ,ug/ml) were compared to that
of 6 control IgGs (500 j.g/ml) in the presence and absence of
TNF (Fig. 4A). /3-Glucuronidase release was increased with
TNF-primed ANCA-stimulated cells (17.5 ± 16.6 jmg of
phenolphthalein) when compared with neutrophils incubated
with ANCA alone (5.0 ± 4.6 Zg of phenolphthalein; P <
0.02). Control IgGs with TNF (4.9 ± 4.8 ;kg of phenolphtha-
lein) or withoutTNF (2.9 ± 1.2 jug ofphenolphthalein) did not
significantly release /B-glucuronidase. In the absence ofTNF
there was no difference between ANCA and control IgG
stimulation. The effects of ANCA-IgGs on ,f-glucuronidase
release was dose dependent (Fig. 4A). Similarly, polyclonal
anti-MPO induced a dose-dependent increase in p-glu-
curonidase release (Fig. 4B). A monoclonal anti-MPO anti-
body produced a dose-dependent response, with degranula-
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FIG. 3. Comparative kinetics of ANCA-induced chemilumines-
cence and superoxide release. The kinetics of a continuous chemilu-
minescence assay (e) and a continuous superoxide dismutase-
inhibitable superoxide release assay (o) were compared after neu-
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FIG. 4. ANCA induced ,B-glucuronidase release. (A) Primary
granule release was measured by the release of ,B-glucuronidase from
neutrophils pretreated with cytochalasin B (5 ,ug/ml) as measured by
the phenolphthalein cleavage from phenolphthalein glucuronic acid
relative to a standard curve. An MPO-ANCA IgG and a control IgG
were incubated for 60 min at 37°C with neutrophils that were
unprimed or primed with TNF (2 ng/ml). (B) Polyclonal anti-human
MPO (100-500 ,ug/ml) with TNF (A) or without TNF (o) produced
dose-dependent ,-glucuronidase release. Monoclonal anti-MPO
(0.5-15 ug/ml) with TNF (A) or without TNF (o) also released
,B-glucuronidase. Only a small and constant amount of lactate dehy-
drogenase (LDH) was released.
tion detected with as little as 0.5 ,g of antibody per ml (Fig.
4B). A monoclonal anti-human DNA antibody did not induce
degranulation. Lactate dehydrogenase measurements indi-
cated that the antibodies were not releasing enzymes as a
result of cytotoxicity (Fig. 4B).
To confirm these ,3-glucuronidase results, NAG release
was also measured. Four representative ANCA IgGs re-
leased 0.0020 + 0.0008 ,umol of NAG per ml per min as
compared with 0.0007 ± 0.0003 kkmol ofNAG per ml per min
for four control IgGs (P < 0.05). Furthermore, a dose-
response curve similar to that shown in Fig. 4 for /-
glucuronidase release was found for NAG release at 100
,ug/ml. MPO-ANCA IgG released 0.0008 jmol of NAG per
ml per min, and at 750 ,ug/ml, it released 0.0031 ,mol ofNAG
per ml per min. In the presence of TNF, a polyclonal
anti-MPO antibody at 100 Ag/ml also induced the release of
0.0053 gmoles of NAG per ml per min. Thus, by using two
FIG. 5. Flow cytometric analysis ofMPO expression on activated
neutrophil cell surfaces. (A) By using a polyclonal anti-human MPO
antibody as the primary reagent and a goat anti-rabbit IgG-
fluorescein isothiocyanate conjugate as the secondary reagent, the
presence of MPO on the surface of neutrophils was measured with
an EPICS Coulter model 753 cell sorter. The presence ofMPO on the
surface of the cells with and without TNF stimulation was measured
at 2 min (Top), 5 min (Middle), and 30 min (Bottom). In each panel,
the control measurement of cells without TNF is to the left and that
with TNF stimulation is to the right. (B) By using polyclonal
anti-human MPO antibody (Top), MPO-ANCA IgG (Middle), and
MPO-ANCA F(ab')2 (Bottom), MPO was identified on the surface of
the cells within 1 min offMet-Leu-Phe stimulation. In each panel, the
control measurement of cells without TNF is to the left and that with
TNF stimulation is to the right.
different assays for primary granule release, ANCA IgGs in
the presence ofTNF induced dose-dependent degranulation.
Flow Cytometry Studies. Flow cytometry studies were
performed to determine whether ANCA antigens, and in
particular MPO, were expressed at the surface of neutrophils
during stimulation. When TNF was used as the primer at 2
ng/ml, MPO was expressed on the surface of neutrophils by
5 min, with a marked increase in antigen expression by 30 min
(Fig. 5A). When fMet-Leu-Phe was used as the activator,
MPO was observed on the cell surface within 30 sec of
stimulation, with a peak effect within 1-2 min (Fig. SB Top).
An MPO-ANCA IgG and its F(ab')2 derivative also recog-
nized increased MPO expression on the surface of fMet-
Leu-Phe-activated cells (Fig. 5B Middle and Bottom). These
results are similar to those reported by Pryzwansky et al.
(35).
DISCUSSION
ANCA were first reported in 1982 in eight patients with
pauci-immune segmental necrotizing glomerulonephritis and
evidence for systemic vasculitis (5). Since then, ANCA have
been identified in patients with a spectrum of necrotizing
vasculitis ranging from renal-limited necrotizing glomerulo-
nephritis to widespread systemic vasculitis, including the
syndromes of Wegener granulomatosis and polyarteritis no-
dosa (1, 5-15).
In the current study we learned that ANCA, in addition to
being important serological markers of vasculitis, are capable
of activating neutrophils in vitro. The interaction of MPO-
ANCA and C-ANCA with neutrophils resulted in the pro-
duction of RGS. RGS were produced when either sera or
purified IgGs were employed. Interestingly, ROS were not
released by purified IgGs from patients with lupus nephritis,
a typical immune complex-mediated nephritis, or by an IgG
from a patient with Goodpasture syndrome, the prototype of
anti-basement membrane antibody-mediated nephritis. The
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release of ROS in the chemiluminescence assay was corrob-
orated by release of superoxide measured on an entirely
different system.
Both ANCA phenotypes also induce, in a dose-dependent
manner, neutrophil degranulation. Primary granule release
was demonstrated by using two independent assay systems
that measure different granule constituents (i.e., 83-glucu-
ronidase and NAG). Commercial polyclonal and monoclonal
anti-human MPO antibodies produced comparable neutro-
phil activation as compared with MPO-ANCA.
The mechanism by which ANCA interact with their target
antigens is not readily apparent since their antigens are found
within cytoplasmic primary granules.' ANCA-induced de-
granulation was markedly enhanced by TNF priming. That
ANCA-induced neutrophil activation is facilitated by TNF
priming is consistent with previous studies in which short
periods of TNF pretreatment enhance the effect's of other
soluble stimuli to induce an oxidative burst and degranulation
(28-31). The flow cytometry studies demonstrate MPO on
the surface of neutrophils after TNF or fMet-Leu-Phe stim-
ulation. Thus, in the process of priming, small quantities of
ANCA antigens, such as MPO, are expressed at the cell
surface and are available to interact with ANCA and initiate
neutrophil activation. Since neutrophils are presumably ac-
tivated to some degree during their procurement and isola-
tion, small amounts of ANCA-related antigens may always be
expressed on the surface of isolated cells. Cytokine priming
invariably enhanced, and in some assays was required for,
ROS production, and degranulation.
The flow cytometry results also shed light on the kinetics
of ANCA activation. When compared to stimuli that induce
activation within a matter of seconds to 1-2 min (35), ANCA
activation is delayed. It is interesting to note that the delayed
surface expression of MPO with TNF pretreatment corre-
lates well with the delayed release of ROS caused by ANCA
stimulation.
MPO is capable of inhibiting neutrophil secretory products
and activation (36, 37). It is conceivable that ANCA, espe-
cially MPO-ANCA, interact with extracellular MPO and
abrogate the inhibitory effects ofMPO-catalyzed'oxidation of
neutrophil secretory products.
Since TNF as well as other cytokines (30) are released into
the circulation during inflammatory diseases, such as infec-
tions, it is possible that they provide an in vivo priming of
neutrophils in ANCA-positive patients that then allows for
ANCA-induced neutrophil activation. This might explain the
observation that the majority of patients with ANCA-
associated disease describe a "flu-like" prodrome before the
onset of vasculitic and nephritic symptoms. Additionally, we
have observed a seasonal variation in the onset of clinical
symptoms of necrotizing vasculitis, with a preponderance of
cases during winter months (38).
The pathogenesis of pauci-immune necrotizing vasculitis
and glomerulonephritis is not attributable to immune com-
plex-mediated or anti-basement membrane antibody-medi-
ated injury. We propose that ANCA, probably in concert
with leukocyte priming factors, induce neutrophils, and pos-
sibly mononuclear phagocytes, to release toxic oxygen rad-
icals and noxious granule constituents that cause vascular
injury in patients with pauci-immune necrotizing vasculitis
and pauci-immune crescentic glomerulonephritis.
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